An interventional study of Transcranial bright light device and Transcranial sham device in Anxiety, sponsored by University of Oulu. Completed at 1 site in Finland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-02-26.
Sponsored by University of Oulu · Not applicable, Interventional, and Treatment
The purpose of this study is to determine if transcranially administered bright light has acute effect on anxiety symptoms.
Subjects (n=30) with anxiety symptoms will be recruited into the study. To be included into the study, subjects have to get at least seven points in BAI(Becks Anxiety Inventory). At the beginning of the study subject will be randomly assigned to 12 minutes of acute transcranial bright light or placebo exposure group. Anxiety symptoms will be measured using Spielberger State-Trait Anxiety Inventory (STAI, form Y1)self-rating questionnaire just before and 10 and 110 minutes after the experiment.
4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.
This study's planned enrollment of 60 is below the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.
Browse Anxiety Disorders studies →University of Oulu is the lead sponsor of 138 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Transcranially administered bright light exposure for 12 minutes
Device: Transcranial bright light device
Transcranially administered sham exposure for 12 minutes
Device: Transcranial sham device
Also known as: Valkee npt 1100
Also known as: Valkee npt 1100
Change in total score of STAI-Y1
STAI-Y1 (Spielberger State-Trait Anxiety Inventory, form Y1)
Time frame: just before exposure, 10 minutes and 110 minutes after the exposure
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Oulu